Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
NCT ID: NCT01179048
Last Updated: 2019-07-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
9341 participants
INTERVENTIONAL
2010-08-31
2015-12-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes
NCT01508949
Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes
NCT01507311
The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes
NCT01617434
Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes
NCT01507285
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
NCT02963922
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Liraglutide
liraglutide
Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
Placebo
placebo
Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
liraglutide
Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
placebo
Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Alabaster, Alabama, United States
Novo Nordisk Investigational Site
Birmingham, Alabama, United States
Novo Nordisk Investigational Site
Birmingham, Alabama, United States
Novo Nordisk Investigational Site
Huntsville, Alabama, United States
Novo Nordisk Investigational Site
Mobile, Alabama, United States
Novo Nordisk Investigational Site
Tempe, Arizona, United States
Novo Nordisk Investigational Site
Little Rock, Arkansas, United States
Novo Nordisk Investigational Site
Little Rock, Arkansas, United States
Novo Nordisk Investigational Site
Anaheim, California, United States
Novo Nordisk Investigational Site
Cerritos, California, United States
Novo Nordisk Investigational Site
Escondido, California, United States
Novo Nordisk Investigational Site
Fresno, California, United States
Novo Nordisk Investigational Site
Los Angeles, California, United States
Novo Nordisk Investigational Site
Los Banos, California, United States
Novo Nordisk Investigational Site
Mission Hills, California, United States
Novo Nordisk Investigational Site
Montclair, California, United States
Novo Nordisk Investigational Site
San Diego, California, United States
Novo Nordisk Investigational Site
Tustin, California, United States
Novo Nordisk Investigational Site
Walnut Creek, California, United States
Novo Nordisk Investigational Site
Watsonville, California, United States
Novo Nordisk Investigational Site
Aurora, Colorado, United States
Novo Nordisk Investigational Site
Denver, Colorado, United States
Novo Nordisk Investigational Site
Newark, Delaware, United States
Novo Nordisk Investigational Site
Bradenton, Florida, United States
Novo Nordisk Investigational Site
Clearwater, Florida, United States
Novo Nordisk Investigational Site
DeLand, Florida, United States
Novo Nordisk Investigational Site
Fort Lauderdale, Florida, United States
Novo Nordisk Investigational Site
Kissimmee, Florida, United States
Novo Nordisk Investigational Site
Miami, Florida, United States
Novo Nordisk Investigational Site
Orlando, Florida, United States
Novo Nordisk Investigational Site
St. Petersburg, Florida, United States
Novo Nordisk Investigational Site
Tampa, Florida, United States
Novo Nordisk Investigational Site
West Palm Beach, Florida, United States
Novo Nordisk Investigational Site
Lawrenceville, Georgia, United States
Novo Nordisk Investigational Site
Roswell, Georgia, United States
Novo Nordisk Investigational Site
Chicago, Illinois, United States
Novo Nordisk Investigational Site
Chicago, Illinois, United States
Novo Nordisk Investigational Site
Chicago, Illinois, United States
Novo Nordisk Investigational Site
Crystal Lake, Illinois, United States
Novo Nordisk Investigational Site
Indianapolis, Indiana, United States
Novo Nordisk Investigational Site
Michigan City, Indiana, United States
Novo Nordisk Investigational Site
West Des Moines, Iowa, United States
Novo Nordisk Investigational Site
Lexington, Kentucky, United States
Novo Nordisk Investigational Site
Louisville, Kentucky, United States
Novo Nordisk Investigational Site
Louisville, Kentucky, United States
Novo Nordisk Investigational Site
Metairie, Louisiana, United States
Novo Nordisk Investigational Site
Monroe, Louisiana, United States
Novo Nordisk Investigational Site
Natchitoches, Louisiana, United States
Novo Nordisk Investigational Site
New Orleans, Louisiana, United States
Novo Nordisk Investigational Site
Baltimore, Maryland, United States
Novo Nordisk Investigational Site
Baltimore, Maryland, United States
Novo Nordisk Investigational Site
Bloomfield Hills, Michigan, United States
Novo Nordisk Investigational Site
Dearborn, Michigan, United States
Novo Nordisk Investigational Site
Interlochen, Michigan, United States
Novo Nordisk Investigational Site
Troy, Michigan, United States
Novo Nordisk Investigational Site
Minneapolis, Minnesota, United States
Novo Nordisk Investigational Site
Springfield, Missouri, United States
Novo Nordisk Investigational Site
St Louis, Missouri, United States
Novo Nordisk Investigational Site
Great Falls, Montana, United States
Novo Nordisk Investigational Site
Omaha, Nebraska, United States
Novo Nordisk Investigational Site
Lebanon, New Hampshire, United States
Novo Nordisk Investigational Site
Nashua, New Hampshire, United States
Novo Nordisk Investigational Site
Mine Hill, New Jersey, United States
Novo Nordisk Investigational Site
Neptune City, New Jersey, United States
Novo Nordisk Investigational Site
Albany, New York, United States
Novo Nordisk Investigational Site
Buffalo, New York, United States
Novo Nordisk Investigational Site
New York, New York, United States
Novo Nordisk Investigational Site
New York, New York, United States
Novo Nordisk Investigational Site
New York, New York, United States
Novo Nordisk Investigational Site
Smithtown, New York, United States
Novo Nordisk Investigational Site
Syracuse, New York, United States
Novo Nordisk Investigational Site
Westfield, New York, United States
Novo Nordisk Investigational Site
Asheville, North Carolina, United States
Novo Nordisk Investigational Site
Burlington, North Carolina, United States
Novo Nordisk Investigational Site
Chapel Hill, North Carolina, United States
Novo Nordisk Investigational Site
Greensboro, North Carolina, United States
Novo Nordisk Investigational Site
Greenville, North Carolina, United States
Novo Nordisk Investigational Site
Monroe, North Carolina, United States
Novo Nordisk Investigational Site
Mooresville, North Carolina, United States
Novo Nordisk Investigational Site
Morehead City, North Carolina, United States
Novo Nordisk Investigational Site
Whiteville, North Carolina, United States
Novo Nordisk Investigational Site
Cadiz, Ohio, United States
Novo Nordisk Investigational Site
Cincinnati, Ohio, United States
Novo Nordisk Investigational Site
Cincinnati, Ohio, United States
Novo Nordisk Investigational Site
Cleveland, Ohio, United States
Novo Nordisk Investigational Site
Marion, Ohio, United States
Novo Nordisk Investigational Site
Middleburg Heights, Ohio, United States
Novo Nordisk Investigational Site
Oklahoma City, Oklahoma, United States
Novo Nordisk Investigational Site
Oklahoma City, Oklahoma, United States
Novo Nordisk Investigational Site
Altoona, Pennsylvania, United States
Novo Nordisk Investigational Site
Beaver, Pennsylvania, United States
Novo Nordisk Investigational Site
Hatfield, Pennsylvania, United States
Novo Nordisk Investigational Site
Philadelphia, Pennsylvania, United States
Novo Nordisk Investigational Site
Philadelphia, Pennsylvania, United States
Novo Nordisk Investigational Site
Pittsburgh, Pennsylvania, United States
Novo Nordisk Investigational Site
Uniontown, Pennsylvania, United States
Novo Nordisk Investigational Site
Charleston, South Carolina, United States
Novo Nordisk Investigational Site
Columbia, South Carolina, United States
Novo Nordisk Investigational Site
Greenville, South Carolina, United States
Novo Nordisk Investigational Site
Greer, South Carolina, United States
Novo Nordisk Investigational Site
Murrells Inlet, South Carolina, United States
Novo Nordisk Investigational Site
Myrtle Beach, South Carolina, United States
Novo Nordisk Investigational Site
Bartlett, Tennessee, United States
Novo Nordisk Investigational Site
Kingsport, Tennessee, United States
Novo Nordisk Investigational Site
Memphis, Tennessee, United States
Novo Nordisk Investigational Site
Nashville, Tennessee, United States
Novo Nordisk Investigational Site
Arlington, Texas, United States
Novo Nordisk Investigational Site
Corpus Christi, Texas, United States
Novo Nordisk Investigational Site
Dallas, Texas, United States
Novo Nordisk Investigational Site
Dallas, Texas, United States
Novo Nordisk Investigational Site
Dallas, Texas, United States
Novo Nordisk Investigational Site
Dallas, Texas, United States
Novo Nordisk Investigational Site
Houston, Texas, United States
Novo Nordisk Investigational Site
Houston, Texas, United States
Novo Nordisk Investigational Site
Longview, Texas, United States
Novo Nordisk Investigational Site
Lubbock, Texas, United States
Novo Nordisk Investigational Site
Odessa, Texas, United States
Novo Nordisk Investigational Site
San Antonio, Texas, United States
Novo Nordisk Investigational Site
San Antonio, Texas, United States
Novo Nordisk Investigational Site
Schertz, Texas, United States
Novo Nordisk Investigational Site
Tomball, Texas, United States
Novo Nordisk Investigational Site
Salt Lake City, Utah, United States
Novo Nordisk Investigational Site
South Burlington, Vermont, United States
Novo Nordisk Investigational Site
Spokane, Washington, United States
Novo Nordisk Investigational Site
Madison, Wisconsin, United States
Novo Nordisk Investigational Site
Blacktown, New South Wales, Australia
Novo Nordisk Investigational Site
Douglas, Queensland, Australia
Novo Nordisk Investigational Site
Herston, Queensland, Australia
Novo Nordisk Investigational Site
Meadowbrook, Queensland, Australia
Novo Nordisk Investigational Site
Keswick, South Australia, Australia
Novo Nordisk Investigational Site
Oaklands Park, South Australia, Australia
Novo Nordisk Investigational Site
Hobart, Tasmania, Australia
Novo Nordisk Investigational Site
Box Hill, Victoria, Australia
Novo Nordisk Investigational Site
Fitzroy, Victoria, Australia
Novo Nordisk Investigational Site
Fremantle, Western Australia, Australia
Novo Nordisk Investigational Site
Graz, , Austria
Novo Nordisk Investigational Site
Vienna, , Austria
Novo Nordisk Investigational Site
Vienna, , Austria
Novo Nordisk Investigational Site
Vienna, , Austria
Novo Nordisk Investigational Site
Vienna, , Austria
Novo Nordisk Investigational Site
Edegem, , Belgium
Novo Nordisk Investigational Site
Ghent, , Belgium
Novo Nordisk Investigational Site
Leuven, , Belgium
Novo Nordisk Investigational Site
Liège, , Belgium
Novo Nordisk Investigational Site
Fortaleza, Ceará, Brazil
Novo Nordisk Investigational Site
Fortaleza, Ceará, Brazil
Novo Nordisk Investigational Site
Fortaleza, Ceará, Brazil
Novo Nordisk Investigational Site
Aparecida de Goiânia, Goiás, Brazil
Novo Nordisk Investigational Site
Curitiba, Paraná, Brazil
Novo Nordisk Investigational Site
Curitiba, Paraná, Brazil
Novo Nordisk Investigational Site
Curitiba, Paraná, Brazil
Novo Nordisk Investigational Site
Belém, Pará, Brazil
Novo Nordisk Investigational Site
Caxias do Sul, Rio Grande do Sul, Brazil
Novo Nordisk Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Novo Nordisk Investigational Site
Campinas, São Paulo, Brazil
Novo Nordisk Investigational Site
Campinas, São Paulo, Brazil
Novo Nordisk Investigational Site
Mogi das Cruzes, São Paulo, Brazil
Novo Nordisk Investigational Site
São Paulo, São Paulo, Brazil
Novo Nordisk Investigational Site
São Paulo, São Paulo, Brazil
Novo Nordisk Investigational Site
São Paulo, São Paulo, Brazil
Novo Nordisk Investigational Site
São Paulo, São Paulo, Brazil
Novo Nordisk Investigational Site
São Paulo, São Paulo, Brazil
Novo Nordisk Investigational Site
São Paulo, São Paulo, Brazil
Novo Nordisk Investigational Site
Aracajú, , Brazil
Novo Nordisk Investigational Site
Belo Horizonte, , Brazil
Novo Nordisk Investigational Site
Campinas, , Brazil
Novo Nordisk Investigational Site
Curitiba, , Brazil
Novo Nordisk Investigational Site
Fortaleza, , Brazil
Novo Nordisk Investigational Site
Goiânia, , Brazil
Novo Nordisk Investigational Site
Joinville, , Brazil
Novo Nordisk Investigational Site
Marília, , Brazil
Novo Nordisk Investigational Site
Porto Alegre, , Brazil
Novo Nordisk Investigational Site
Recife, , Brazil
Novo Nordisk Investigational Site
Rio de Janeiro, , Brazil
Novo Nordisk Investigational Site
Rio de Janeiro, , Brazil
Novo Nordisk Investigational Site
Santos, , Brazil
Novo Nordisk Investigational Site
São Paulo, , Brazil
Novo Nordisk Investigational Site
São Paulo, , Brazil
Novo Nordisk Investigational Site
São Paulo, , Brazil
Novo Nordisk Investigational Site
Edmonton, Alberta, Canada
Novo Nordisk Investigational Site
Vancouver, British Columbia, Canada
Novo Nordisk Investigational Site
Winnipeg, Manitoba, Canada
Novo Nordisk Investigational Site
St. John's, Newfoundland and Labrador, Canada
Novo Nordisk Investigational Site
Halifax, Nova Scotia, Canada
Novo Nordisk Investigational Site
Cambridge, Ontario, Canada
Novo Nordisk Investigational Site
Cornwall, Ontario, Canada
Novo Nordisk Investigational Site
London, Ontario, Canada
Novo Nordisk Investigational Site
London, Ontario, Canada
Novo Nordisk Investigational Site
Mississauga, Ontario, Canada
Novo Nordisk Investigational Site
Scarborough Village, Ontario, Canada
Novo Nordisk Investigational Site
Smiths Falls, Ontario, Canada
Novo Nordisk Investigational Site
Thunder Bay, Ontario, Canada
Novo Nordisk Investigational Site
Toronto, Ontario, Canada
Novo Nordisk Investigational Site
Toronto, Ontario, Canada
Novo Nordisk Investigational Site
Montreal, Quebec, Canada
Novo Nordisk Investigational Site
Québec, , Canada
Novo Nordisk Investigational Site
Québec, , Canada
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Novo Nordisk Investigational Site
Xiamen, Fujian, China
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Novo Nordisk Investigational Site
Zhenjiang, Jiangsu, China
Novo Nordisk Investigational Site
Qingdao, Shandong, China
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Novo Nordisk Investigational Site
Pilsen, , Czechia
Novo Nordisk Investigational Site
Prague, , Czechia
Novo Nordisk Investigational Site
Aalborg, , Denmark
Novo Nordisk Investigational Site
Århus C, , Denmark
Novo Nordisk Investigational Site
Esbjerg, , Denmark
Novo Nordisk Investigational Site
Gentofte Municipality, , Denmark
Novo Nordisk Investigational Site
Hvidovre, , Denmark
Novo Nordisk Investigational Site
Odense, , Denmark
Novo Nordisk Investigational Site
Kuopio, , Finland
Novo Nordisk Investigational Site
Lahti, , Finland
Novo Nordisk Investigational Site
Oulu, , Finland
Novo Nordisk Investigational Site
Tampere, , Finland
Novo Nordisk Investigational Site
Vantaa, , Finland
Novo Nordisk Investigational Site
Corbeil-Essonnes, , France
Novo Nordisk Investigational Site
Jarny, , France
Novo Nordisk Investigational Site
Nîmes, , France
Novo Nordisk Investigational Site
Paris, , France
Novo Nordisk Investigational Site
Angermünde/OT Wolletz, , Germany
Novo Nordisk Investigational Site
Aschaffenburg, , Germany
Novo Nordisk Investigational Site
Berlin, , Germany
Novo Nordisk Investigational Site
Berlin, , Germany
Novo Nordisk Investigational Site
Dillingen, , Germany
Novo Nordisk Investigational Site
Dresden, , Germany
Novo Nordisk Investigational Site
Elsterwerda, , Germany
Novo Nordisk Investigational Site
Essen, , Germany
Novo Nordisk Investigational Site
Falkensee, , Germany
Novo Nordisk Investigational Site
Gifhorn, , Germany
Novo Nordisk Investigational Site
Hamburg, , Germany
Novo Nordisk Investigational Site
Karlsbad, , Germany
Novo Nordisk Investigational Site
Leipzig, , Germany
Novo Nordisk Investigational Site
Leipzig, , Germany
Novo Nordisk Investigational Site
Ludwigshafen, , Germany
Novo Nordisk Investigational Site
Mannheim, , Germany
Novo Nordisk Investigational Site
München, , Germany
Novo Nordisk Investigational Site
Oldenburg, , Germany
Novo Nordisk Investigational Site
Saint Ingbert-Oberwürzbach, , Germany
Novo Nordisk Investigational Site
Schkeuditz, , Germany
Novo Nordisk Investigational Site
Schweinfurt, , Germany
Novo Nordisk Investigational Site
Ulm, , Germany
Novo Nordisk Investigational Site
Villingen-Schwenningen, , Germany
Novo Nordisk Investigational Site
Wangen, , Germany
Novo Nordisk Investigational Site
Athens, , Greece
Novo Nordisk Investigational Site
Athens, , Greece
Novo Nordisk Investigational Site
Crete, , Greece
Novo Nordisk Investigational Site
Thessaloniki, , Greece
Novo Nordisk Investigational Site
Hyderabad, Andhra Pradesh, India
Novo Nordisk Investigational Site
Hyderbad, Andhra Pradesh, India
Novo Nordisk Investigational Site
Guwahati, Assam, India
Novo Nordisk Investigational Site
Karnāl, Haryana, India
Novo Nordisk Investigational Site
Bangalore, Karnataka, India
Novo Nordisk Investigational Site
Bangalore, Karnataka, India
Novo Nordisk Investigational Site
Bangalore, Karnataka, India
Novo Nordisk Investigational Site
Manipal, Karnataka, India
Novo Nordisk Investigational Site
Kochi, Kerala, India
Novo Nordisk Investigational Site
Indore, Madhya Pradesh, India
Novo Nordisk Investigational Site
Mumbai, Maharashtra, India
Novo Nordisk Investigational Site
Chandigarh, Punjab, India
Novo Nordisk Investigational Site
Chennai, Tamil Nadu, India
Novo Nordisk Investigational Site
Chennai, Tamil Nadu, India
Novo Nordisk Investigational Site
Madurai, Tamil Nadu, India
Novo Nordisk Investigational Site
Vellore, Tamil Nadu, India
Novo Nordisk Investigational Site
Kolkata, West Bengal, India
Novo Nordisk Investigational Site
Thriruvananthapuram, , India
Novo Nordisk Investigational Site
Dublin, , Ireland
Novo Nordisk Investigational Site
Dublin, , Ireland
Novo Nordisk Investigational Site
Haifa, , Israel
Novo Nordisk Investigational Site
Haifa, , Israel
Novo Nordisk Investigational Site
Jerusalem, , Israel
Novo Nordisk Investigational Site
Petah Tikva, , Israel
Novo Nordisk Investigational Site
Tel Litwinsky, , Israel
Novo Nordisk Investigational Site
Bologna, , Italy
Novo Nordisk Investigational Site
Catanzaro, , Italy
Novo Nordisk Investigational Site
Chieti, , Italy
Novo Nordisk Investigational Site
Florence, , Italy
Novo Nordisk Investigational Site
Latina, , Italy
Novo Nordisk Investigational Site
Lucca, , Italy
Novo Nordisk Investigational Site
Milan, , Italy
Novo Nordisk Investigational Site
Padua, , Italy
Novo Nordisk Investigational Site
Palermo, , Italy
Novo Nordisk Investigational Site
Roma, , Italy
Novo Nordisk Investigational Site
Roma, , Italy
Novo Nordisk Investigational Site
Tijuana, Baja California Norte, Mexico
Novo Nordisk Investigational Site
Guadalajara, Jalisco, Mexico
Novo Nordisk Investigational Site
Guadalajara, Jalisco, Mexico
Novo Nordisk Investigational Site
Aguascalientes, , Mexico
Novo Nordisk Investigational Site
Durango, , Mexico
Novo Nordisk Investigational Site
Durango, , Mexico
Novo Nordisk Investigational Site
Monterrey, , Mexico
Novo Nordisk Investigational Site
San Luis Potosí City, , Mexico
Novo Nordisk Investigational Site
Amsterdam, , Netherlands
Novo Nordisk Investigational Site
Eindhoven, , Netherlands
Novo Nordisk Investigational Site
Etten-Leur, , Netherlands
Novo Nordisk Investigational Site
Goes, , Netherlands
Novo Nordisk Investigational Site
Groningen, , Netherlands
Novo Nordisk Investigational Site
Hoogeveen, , Netherlands
Novo Nordisk Investigational Site
Maastricht, , Netherlands
Novo Nordisk Investigational Site
Nijmegen, , Netherlands
Novo Nordisk Investigational Site
Utrecht, , Netherlands
Novo Nordisk Investigational Site
Oslo, , Norway
Novo Nordisk Investigational Site
Oslo, , Norway
Novo Nordisk Investigational Site
Stavanger, , Norway
Novo Nordisk Investigational Site
Trondheim, , Norway
Novo Nordisk Investigational Site
Tønsberg, , Norway
Novo Nordisk Investigational Site
Bialystok, , Poland
Novo Nordisk Investigational Site
Bydgoszcz, , Poland
Novo Nordisk Investigational Site
Katowice, , Poland
Novo Nordisk Investigational Site
Krakow, , Poland
Novo Nordisk Investigational Site
Krakow, , Poland
Novo Nordisk Investigational Site
Krakow, , Poland
Novo Nordisk Investigational Site
Lodz, , Poland
Novo Nordisk Investigational Site
Poznan, , Poland
Novo Nordisk Investigational Site
Puławy, , Poland
Novo Nordisk Investigational Site
Ruda Śląska, , Poland
Novo Nordisk Investigational Site
Warsaw, , Poland
Novo Nordisk Investigational Site
Warsaw, , Poland
Novo Nordisk Investigational Site
Wroclaw, , Poland
Novo Nordisk Investigational Site
Bayamón, , Puerto Rico
Novo Nordisk Investigational Site
Caguas, , Puerto Rico
Novo Nordisk Investigational Site
Craiova, Dolj, Romania
Novo Nordisk Investigational Site
Târgu Mureş, Mureș County, Romania
Novo Nordisk Investigational Site
Timișoara, Timiș County, Romania
Novo Nordisk Investigational Site
Bacau, , Romania
Novo Nordisk Investigational Site
Bucharest, , Romania
Novo Nordisk Investigational Site
Constanța, , Romania
Novo Nordisk Investigational Site
Deva, , Romania
Novo Nordisk Investigational Site
Iași, , Romania
Novo Nordisk Investigational Site
Satu Mare, , Romania
Novo Nordisk Investigational Site
Sibiu, , Romania
Novo Nordisk Investigational Site
Arkhangelsk, , Russia
Novo Nordisk Investigational Site
Arkhangelsk, , Russia
Novo Nordisk Investigational Site
Barnaul, , Russia
Novo Nordisk Investigational Site
Kazan', , Russia
Novo Nordisk Investigational Site
Moscow, , Russia
Novo Nordisk Investigational Site
Moscow, , Russia
Novo Nordisk Investigational Site
Moscow, , Russia
Novo Nordisk Investigational Site
Moscow, , Russia
Novo Nordisk Investigational Site
Nizhny Novgorod, , Russia
Novo Nordisk Investigational Site
Penza, , Russia
Novo Nordisk Investigational Site
Saratov, , Russia
Novo Nordisk Investigational Site
Smolensk, , Russia
Novo Nordisk Investigational Site
Tyumen, , Russia
Novo Nordisk Investigational Site
Yaroslavl, , Russia
Novo Nordisk Investigational Site
Belgrade, , Serbia
Novo Nordisk Investigational Site
Bloemfontein, Free State, South Africa
Novo Nordisk Investigational Site
Johannesburg, Gauteng, South Africa
Novo Nordisk Investigational Site
Johannesburg, Gauteng, South Africa
Novo Nordisk Investigational Site
Lenasia, Gauteng, South Africa
Novo Nordisk Investigational Site
Midrand, Gauteng, South Africa
Novo Nordisk Investigational Site
Pretoria, Gauteng, South Africa
Novo Nordisk Investigational Site
Pretoria, Gauteng, South Africa
Novo Nordisk Investigational Site
Pretoria, Gauteng, South Africa
Novo Nordisk Investigational Site
Durban, KwaZulu-Natal, South Africa
Novo Nordisk Investigational Site
Durban, KwaZulu-Natal, South Africa
Novo Nordisk Investigational Site
Durban, KwaZulu-Natal, South Africa
Novo Nordisk Investigational Site
Tongaat, KwaZulu-Natal, South Africa
Novo Nordisk Investigational Site
Cape Town, Western Cape, South Africa
Novo Nordisk Investigational Site
Somerset West, Western Cape, South Africa
Novo Nordisk Investigational Site
Alberton, , South Africa
Novo Nordisk Investigational Site
Cape Town, , South Africa
Novo Nordisk Investigational Site
Goyang, , South Korea
Novo Nordisk Investigational Site
Seongnam-si, , South Korea
Novo Nordisk Investigational Site
Seoul, , South Korea
Novo Nordisk Investigational Site
Seoul, , South Korea
Novo Nordisk Investigational Site
Seoul, , South Korea
Novo Nordisk Investigational Site
A Coruña, , Spain
Novo Nordisk Investigational Site
Almería, , Spain
Novo Nordisk Investigational Site
Barcelona, , Spain
Novo Nordisk Investigational Site
Madrid, , Spain
Novo Nordisk Investigational Site
Mora de Ebre, , Spain
Novo Nordisk Investigational Site
Mostoles - Madrid -, , Spain
Novo Nordisk Investigational Site
Palma de Mallorca, , Spain
Novo Nordisk Investigational Site
Pozuelo de Alarcón, , Spain
Novo Nordisk Investigational Site
Seville, , Spain
Novo Nordisk Investigational Site
Seville, , Spain
Novo Nordisk Investigational Site
Valladolid, , Spain
Novo Nordisk Investigational Site
Gothenburg, , Sweden
Novo Nordisk Investigational Site
Malmo, , Sweden
Novo Nordisk Investigational Site
Örebro, , Sweden
Novo Nordisk Investigational Site
Stockholm, , Sweden
Novo Nordisk Investigational Site
Stockholm, , Sweden
Novo Nordisk Investigational Site
Stockholm, , Sweden
Novo Nordisk Investigational Site
Changhua, , Taiwan
Novo Nordisk Investigational Site
Kaoshiung, , Taiwan
Novo Nordisk Investigational Site
Tainan City, , Taiwan
Novo Nordisk Investigational Site
Taoyuan District, , Taiwan
Novo Nordisk Investigational Site
Ankara, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Ankara, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Antalya, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Bursa, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Gaziantep, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Istanbul, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Istanbul, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Istanbul, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Istanbul, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Istanbul, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Istanbul, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Istanbul, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Istanbul, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Izmir, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Izmir, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Kayseri, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Dubai, , United Arab Emirates
Novo Nordisk Investigational Site
Dubai, , United Arab Emirates
Novo Nordisk Investigational Site
Aberdeen, , United Kingdom
Novo Nordisk Investigational Site
Birmingham, , United Kingdom
Novo Nordisk Investigational Site
Bristol, , United Kingdom
Novo Nordisk Investigational Site
Coventry, , United Kingdom
Novo Nordisk Investigational Site
Devon, , United Kingdom
Novo Nordisk Investigational Site
Dundee, , United Kingdom
Novo Nordisk Investigational Site
Edinburgh, , United Kingdom
Novo Nordisk Investigational Site
Glasgow, , United Kingdom
Novo Nordisk Investigational Site
Guildford, , United Kingdom
Novo Nordisk Investigational Site
Hull, , United Kingdom
Novo Nordisk Investigational Site
Livington, , United Kingdom
Novo Nordisk Investigational Site
London, , United Kingdom
Novo Nordisk Investigational Site
Manchester, , United Kingdom
Novo Nordisk Investigational Site
Norwich, , United Kingdom
Novo Nordisk Investigational Site
Nuneaton, , United Kingdom
Novo Nordisk Investigational Site
Plymouth, , United Kingdom
Novo Nordisk Investigational Site
St Helens, , United Kingdom
Novo Nordisk Investigational Site
Swansea, , United Kingdom
Novo Nordisk Investigational Site
Torquay, , United Kingdom
Novo Nordisk Investigational Site
West Midlands, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Verma S, Bain SC, Monk Fries T, Mazer CD, Nauck MA, Pratley RE, Rasmussen S, Saevereid HA, Zinman B, Buse JB. Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. Diabetes Obes Metab. 2019 Jul;21(7):1745-1751. doi: 10.1111/dom.13698. Epub 2019 Apr 2.
Hinton W, Feher M, Munro N, Walker M, de Lusignan S. Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network. Diabetes Obes Metab. 2019 Jul;21(7):1661-1667. doi: 10.1111/dom.13710. Epub 2019 Apr 11.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
Petrie JR, Marso SP, Bain SC, Franek E, Jacob S, Masmiquel L, Leiter LA, Haluzik M, Satman I, Omar M, Shestakova M, Van Gaal L, Mann JF, Baeres FM, Zinman B, Poulter NR; LEADER investigators. LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial. J Hypertens. 2016 Jun;34(6):1140-50. doi: 10.1097/HJH.0000000000000890.
Masmiquel L, Leiter LA, Vidal J, Bain S, Petrie J, Franek E, Raz I, Comlekci A, Jacob S, van Gaal L, Baeres FM, Marso SP, Eriksson M; LEADER investigators. LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovasc Diabetol. 2016 Feb 10;15:29. doi: 10.1186/s12933-016-0341-5.
Satman I, R Rea R, Eriksson M, Mosenzon O, Pratley R, M Baeres F, D Orsted D, F Mann J; LEADER Trial Investigators. LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population. J Diabetes Complications. 2016 Nov-Dec;30(8):1631-1639. doi: 10.1016/j.jdiacomp.2016.06.001. Epub 2016 Jun 3.
Rutten GE, Tack CJ, Pieber TR, Comlekci A, Orsted DD, Baeres FM, Marso SP, Buse JB; LEADER Investigators. LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ. Diabetol Metab Syndr. 2016 Jun 2;8:37. doi: 10.1186/s13098-016-0153-5. eCollection 2016.
Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Pocock S, Steinberg WM, Bergenstal RM, Mann JF, Ravn LS, Frandsen KB, Moses AC, Buse JB. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013 Nov;166(5):823-30.e5. doi: 10.1016/j.ahj.2013.07.012. Epub 2013 Oct 2.
Steinberg WM, Nauck MA, Zinman B, Daniels GH, Bergenstal RM, Mann JF, Steen Ravn L, Moses AC, Stockner M, Baeres FM, Marso SP, Buse JB; LEADER Trial investigators. LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. Pancreas. 2014 Nov;43(8):1223-31. doi: 10.1097/MPA.0000000000000229.
Daniels GH, Hegedus L, Marso SP, Nauck MA, Zinman B, Bergenstal RM, Mann JF, Derving Karsbol J, Moses AC, Buse JB, Tuttle RM; LEADER Trial Investigators. LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. Diabetes Obes Metab. 2015 May;17(5):477-86. doi: 10.1111/dom.12444. Epub 2015 Feb 23.
Steinberg WM, Buse JB, Ghorbani MLM, Orsted DD, Nauck MA; LEADER Steering Committee; LEADER Trial Investigators. Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. Diabetes Care. 2017 Jul;40(7):966-972. doi: 10.2337/dc16-2747. Epub 2017 May 5.
Mann JFE, Orsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornoe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.
Hegedus L, Sherman SI, Tuttle RM, von Scholten BJ, Rasmussen S, Karsbol JD, Daniels GH; LEADER Publication Committee on behalf of the LEADER Trial Investigators. No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. Diabetes Care. 2018 Mar;41(3):620-622. doi: 10.2337/dc17-1956. Epub 2017 Dec 26.
Marso SP, Nauck MA, Monk Fries T, Rasmussen S, Treppendahl MB, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). Am J Cardiol. 2018 Jun 15;121(12):1467-1470. doi: 10.1016/j.amjcard.2018.02.030. Epub 2018 Mar 15.
Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulter NR, Pratley RE, Zinman B, Michelsen MM, Monk Fries T, Rasmussen S, Leiter LA; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. Circulation. 2018 May 15;137(20):2179-2183. doi: 10.1161/CIRCULATIONAHA.118.033898. No abstract available.
Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. Diabetes Care. 2018 Aug;41(8):1663-1671. doi: 10.2337/dc17-1825. Epub 2018 Jun 13.
Zinman B, Marso SP, Christiansen E, Calanna S, Rasmussen S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. Diabetes Care. 2018 Aug;41(8):1783-1791. doi: 10.2337/dc17-2677. Epub 2018 Jun 14.
Nauck MA, Tornoe K, Rasmussen S, Treppendahl MB, Marso SP; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. Diab Vasc Dis Res. 2018 Sep;15(5):465-468. doi: 10.1177/1479164118783935. Epub 2018 Jun 27.
Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornoe K, Pratley RE; LEADER Publication Committee on behalf of the LEADER Trial Investigators. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. Diabetes Care. 2018 Oct;41(10):2229-2235. doi: 10.2337/dc18-1094. Epub 2018 Aug 2.
Verma S, Leiter LA, Mazer CD, Bain SC, Buse J, Marso S, Nauck M, Zinman B, Bosch-Traberg H, Rasmussen S, Michelsen MM, Bhatt DL. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. Circulation. 2018 Oct 9;138(15):1605-1607. doi: 10.1161/CIRCULATIONAHA.118.036862. No abstract available.
Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Circulation. 2018 Dec 18;138(25):2908-2918. doi: 10.1161/CIRCULATIONAHA.118.036418.
Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Orsted DD, Monk Fries T, Rasmussen S, Marso SP. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation. 2018 Dec 18;138(25):2884-2894. doi: 10.1161/CIRCULATIONAHA.118.034516.
Nauck MA, Buse JB, Mann JFE, Pocock S, Bosch-Traberg H, Frimer-Larsen H, Ye Q, Gray A; LEADER Publication Committee for the LEADER Trial Investigators. Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. Diabetes Obes Metab. 2019 Mar;21(3):525-532. doi: 10.1111/dom.13547. Epub 2018 Oct 25.
Zinman B, Nauck MA, Bosch-Traberg H, Frimer-Larsen H, Orsted DD, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Liraglutide and Glycaemic Outcomes in the LEADER Trial. Diabetes Ther. 2018 Dec;9(6):2383-2392. doi: 10.1007/s13300-018-0524-z. Epub 2018 Nov 3.
Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nauck MA, Pratley R, Rea RR, Kerr Saraiva JF, Rasmussen S, Tornoe K, von Scholten BJ, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. Ann Intern Med. 2019 Mar 19;170(6):423-426. doi: 10.7326/M18-1569. Epub 2018 Dec 4. No abstract available.
Natale P, Green SC, Tunnicliffe DJ, Pellegrino G, Toyama T, Strippoli GF. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.
Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, Sejersten Ripa M, Bonaca MP. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab. 2022 Jul;24(7):1288-1299. doi: 10.1111/dom.14700. Epub 2022 Apr 11.
Heller SR, Geybels MS, Iqbal A, Liu L, Wagner L, Chow E. A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study. Diabetologia. 2022 Jan;65(1):55-64. doi: 10.1007/s00125-021-05556-7. Epub 2021 Oct 26.
Persson F, Bain SC, Mosenzon O, Heerspink HJL, Mann JFE, Pratley R, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Rossing P; LEADER Trial Investigators. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Diabetes Care. 2021 Apr;44(4):1020-1026. doi: 10.2337/dc20-1622. Epub 2021 Jan 27.
Verma S, McGuire DK, Bain SC, Bhatt DL, Leiter LA, Mazer CD, Monk Fries T, Pratley RE, Rasmussen S, Vrazic H, Zinman B, Buse JB. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020 Dec;22(12):2487-2492. doi: 10.1111/dom.14160. Epub 2020 Sep 4.
Crowley MJ, McGuire DK, Alexopoulos AS, Jensen TJ, Rasmussen S, Saevereid HA, Verma S, Buse JB. Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. Diabetes Care. 2020 Sep;43(9):e108-e110. doi: 10.2337/dc20-0437. Epub 2020 Jul 9. No abstract available.
Verma S, Bain SC, Honore JB, F E Mann J, A Nauck M, E Pratley R, Rasmussen S, Sejersten Ripa M, Zinman B, Buse JB. Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. Diabetes Obes Metab. 2020 Nov;22(11):2193-2198. doi: 10.1111/dom.14140. Epub 2020 Aug 12.
Leiter LA, Bain SC, Bhatt DL, Buse JB, Mazer CD, Pratley RE, Rasmussen S, Ripa MS, Vrazic H, Verma S. The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020 Sep;22(9):1690-1695. doi: 10.1111/dom.14079. Epub 2020 Jun 3.
Buse JB, Bain SC, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Pratley RE, Linder M, Monk Fries T, Orsted DD, Zinman B; LEADER Trial Investigators. Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care. 2020 Jul;43(7):1546-1552. doi: 10.2337/dc19-2251. Epub 2020 May 4.
Marso SP, Baeres FMM, Bain SC, Goldman B, Husain M, Nauck MA, Poulter NR, Pratley RE, Thomsen AB, Buse JB; LEADER Trial Investigators. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. J Am Coll Cardiol. 2020 Mar 17;75(10):1128-1141. doi: 10.1016/j.jacc.2019.12.063.
Mann JFE, Fonseca VA, Poulter NR, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Mosenzon O; LEADER Trial Investigators. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clin J Am Soc Nephrol. 2020 Apr 7;15(4):465-473. doi: 10.2215/CJN.11881019. Epub 2020 Mar 4.
Nauck MA, Kreiner E, Rasmussen S, Saevereid HA, Buse JB; LEADER Trial Investigators. Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920. Diabetes Care. 2020 Feb;43(2):e30-e31. doi: 10.2337/dci19-0067. No abstract available.
Verma S, Bain SC, Buse JB, Idorn T, Rasmussen S, Orsted DD, Nauck MA. Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019 Dec 1;4(12):1214-1220. doi: 10.1001/jamacardio.2019.3080.
Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care. 2019 Oct;42(10):1912-1920. doi: 10.2337/dc19-0415. Epub 2019 Aug 9.
Tack CJ, Jacob S, Desouza C, Bain SC, Buse JB, Nauck MA, Petrie JR, Poulter NR, Pratley RE, Stegmann HVBK, Bosch-Traberg H, Startseva E, Zinman B; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. Diabetes Obes Metab. 2019 Nov;21(11):2450-2458. doi: 10.1111/dom.13826. Epub 2019 Jul 7.
Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population. Am J Manag Care. 2018 Apr;24(8 Suppl):S146-S155.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-012201-19
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
U1111-1113-7090
Identifier Type: OTHER
Identifier Source: secondary_id
CTR20130003
Identifier Type: OTHER
Identifier Source: secondary_id
EX2211-3748
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.